Kirr Marbach & Co. LLC IN Has $4.98 Million Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Kirr Marbach & Co. LLC IN lifted its holdings in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) by 63.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,870 shares of the medical instruments supplier's stock after buying an additional 13,951 shares during the period. Kirr Marbach & Co. LLC IN owned about 0.15% of ICU Medical worth $4,981,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Harvest Fund Management Co. Ltd acquired a new stake in shares of ICU Medical in the fourth quarter worth $33,000. Quarry LP boosted its position in ICU Medical by 764.3% during the fourth quarter. Quarry LP now owns 242 shares of the medical instruments supplier's stock valued at $38,000 after purchasing an additional 214 shares during the last quarter. Murphy & Mullick Capital Management Corp acquired a new stake in ICU Medical during the fourth quarter valued at $52,000. Venturi Wealth Management LLC boosted its position in ICU Medical by 64.0% during the fourth quarter. Venturi Wealth Management LLC now owns 528 shares of the medical instruments supplier's stock valued at $82,000 after purchasing an additional 206 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its position in ICU Medical by 88.8% during the fourth quarter. Russell Investments Group Ltd. now owns 638 shares of the medical instruments supplier's stock valued at $99,000 after purchasing an additional 300 shares during the last quarter. Institutional investors and hedge funds own 96.10% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. KeyCorp reduced their price objective on ICU Medical from $209.00 to $191.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a research report on Sunday, May 18th. Needham & Company LLC reissued a "hold" rating on shares of ICU Medical in a research report on Tuesday, April 8th. Finally, Raymond James Financial reduced their price objective on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating for the company in a research report on Friday, May 9th. One analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $192.67.

ICU Medical Price Performance

NASDAQ ICUI opened at $128.07 on Tuesday. ICU Medical, Inc. has a fifty-two week low of $111.97 and a fifty-two week high of $196.26. The stock's 50-day moving average is $134.70 and its two-hundred day moving average is $147.30. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.59 and a quick ratio of 1.52. The firm has a market cap of $3.15 billion, a P/E ratio of -33.44 and a beta of 0.88.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.72 earnings per share for the quarter, beating the consensus estimate of $1.23 by $0.49. ICU Medical had a positive return on equity of 6.75% and a negative net margin of 3.87%. The company had revenue of $599.49 million for the quarter, compared to analyst estimates of $574.15 million. During the same period last year, the company earned $0.96 earnings per share. The business's revenue was up 6.7% compared to the same quarter last year. On average, analysts anticipate that ICU Medical, Inc. will post 4.11 earnings per share for the current fiscal year.

Insider Buying and Selling at ICU Medical

In other ICU Medical news, COO Christian B. Voigtlander sold 5,556 shares of the firm's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $138.65, for a total value of $770,339.40. Following the sale, the chief operating officer now owns 2,389 shares of the company's stock, valued at $331,234.85. This trade represents a 69.93% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director David C. Greenberg sold 1,942 shares of the firm's stock in a transaction that occurred on Tuesday, May 13th. The shares were sold at an average price of $143.66, for a total value of $278,987.72. Following the completion of the sale, the director now directly owns 6,760 shares in the company, valued at $971,141.60. This trade represents a 22.32% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 36,097 shares of company stock worth $4,860,156 over the last three months. Corporate insiders own 1.50% of the company's stock.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.